Inactivated SARS-CoV-2 Vaccine Well Tolerated in Phase 1/2 Trial
Neutralizing antibody geometric mean titers higher in vaccine group at day 42 in phase 1 trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.